<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: uncertainties", fill: "#e49b0f"},
{source: "2: uncertainties", target: "2: currently unaware which", fill: "#e49b0f"},
{source: "2: currently unaware which", target: "2: adversely", fill: "#e49b0f"},
{source: "2: adversely", target: "2: operations", fill: "#e49b0f"},
{source: "2: uncertainties", target: "3: uncertainties", fill: "#cd5b45"},
{source: "3: uncertainties", target: "3: risks listed", fill: "#cd5b45"},
{source: "3: risks listed", target: "3: operations earnings", fill: "#cd5b45"},
{source: "3: operations earnings", target: "3: financial condition could", fill: "#cd5b45"},
{source: "3: financial condition could", target: "3: materially harmed which", fill: "#cd5b45"},
{source: "3: materially harmed which", target: "3: would most likely adversely affect", fill: "#cd5b45"},
{source: "3: would most likely adversely affect", target: "3: trading price", fill: "#cd5b45"},
{source: "3: trading price", target: "3: common stock", fill: "#cd5b45"},
{source: "3: uncertainties", target: "7: expansion program", fill: "#ff7518"},
{source: "7: expansion program", target: "7: development", fill: "#ff7518"},
{source: "7: expansion program", target: "8: commencement", fill: "#ff6fff"},
{source: "8: commencement", target: "8: operations", fill: "#ff6fff"},
{source: "8: operations", target: "8: facilities", fill: "#ff6fff"},
{source: "8: commencement", target: "9: operational costs", fill: "#ffa6c9"},
{source: "9: operational costs", target: "9: reach maturity", fill: "#ffa6c9"},
{source: "9: reach maturity", target: "9: dialysis treatments", fill: "#ffa6c9"},
{source: "9: operational costs", target: "11: Dialysis ", fill: "#5d3954"},
{source: "11: Dialysis ", target: "11: operations", fill: "#5d3954"},
{source: "11: operations", target: "11: government regulation", fill: "#5d3954"},
{source: "11: government regulation", target: "11: regulations", fill: "#5d3954"},
{source: "11: regulations", target: "11: government regulations which", fill: "#5d3954"},
{source: "11: government regulations which", target: "11: licensing requirements", fill: "#5d3954"},
{source: "11: licensing requirements", target: "11: requirements", fill: "#5d3954"},
{source: "11: requirements", target: "11: each dialysis center", fill: "#5d3954"},
{source: "11: each dialysis center", target: "11: reimbursement", fill: "#5d3954"},
{source: "11: reimbursement", target: "11: patient services", fill: "#5d3954"},
{source: "11: patient services", target: "11: patient referral prohibitions broad federal", fill: "#5d3954"},
{source: "11: patient referral prohibitions broad federal", target: "11: prohibitions", fill: "#5d3954"},
{source: "11: prohibitions", target: "11: health care reimbursement", fill: "#5d3954"},
{source: "11: health care reimbursement", target: "11: abuse regulations", fill: "#5d3954"},
{source: "11: abuse regulations", target: "11: health safety", fill: "#5d3954"},
{source: "11: health safety", target: "11: environmental compliance", fill: "#5d3954"},
{source: "11: environmental compliance", target: "11: expanded protection", fill: "#5d3954"},
{source: "11: expanded protection", target: "11: personal medical data", fill: "#5d3954"},
{source: "11: personal medical data", target: "11: electronic", fill: "#5d3954"},
{source: "11: electronic", target: "11: transactions", fill: "#5d3954"},
{source: "11: transactions", target: "11: code sets unique identifiers", fill: "#5d3954"},
{source: "11: code sets unique identifiers", target: "11: medical waste disposal regulations", fill: "#5d3954"},
{source: "11: medical waste disposal regulations", target: "11: legislative", fill: "#5d3954"},
{source: "11: legislative", target: "11: interpretations", fill: "#5d3954"},
{source: "11: Dialysis ", target: "38: Decreases in Medicare and Medicaid ", fill: "#43b3ae"},
{source: "38: Decreases in Medicare and Medicaid ", target: "38: treatments", fill: "#43b3ae"},
{source: "38: treatments", target: "38: adversely", fill: "#43b3ae"},
{source: "38: adversely", target: "38: profitability", fill: "#43b3ae"},
{source: "38: Decreases in Medicare and Medicaid ", target: "START_HERE", fill: "#43b3ae"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Home Improvement Retail</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Net_income">Net income</a></td>
      <td>In business and accounting, net income (also total comprehensive income, net earnings, net profit, bottom line, sales profit, or credit sales) is an entity's income minus cost of goods sold, expenses, depreciation and amortization, interest, and taxes for an accounting period.It is computed as the residual of all revenues and gains less all expenses and losses for the period, and has also been defined as the net increase in shareholders' equity that results from a company's operations. It is different from gross income, which only deducts the cost of goods sold from revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/NASA_facilities">NASA facilities</a></td>
      <td>There are NASA facilities across the United States and around the world. NASA Headquarters in Washington, DC provides overall guidance and political leadership to the agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Flight_Facilities">Flight Facilities</a></td>
      <td>Flight Facilities is an Australian electronic producer duo that also performs as Hugo &amp; Jimmy. In 2009, they began mixing songs by other artists before crafting their own original material.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facilities_engineering">Facilities engineering</a></td>
      <td>Facilities engineering evolved from "plant engineering" in the early 1990s as U.S. workplaces became more specialized. Practitioners preferred this term because it more accurately reflected the multidisciplinary demands for specialized conditions in a wider variety of indoor environments, not merely manufacturing plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pedestrian_facilities">Pedestrian facilities</a></td>
      <td>Pedestrian facilities include retail shops, museums, mass events (such as festivals or concert halls), hospitals, transport hubs (such as train stations or airports), sports infrastructure (such as stadiums) and religious infrastructures. The transport mode in such infrastructures is mostly walking, with rare exceptions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Attacks_on_U.S._diplomatic_facilities">Attacks on U.S. diplomatic facilities</a></td>
      <td>The United States maintains numerous embassies and consulates around the world, many of which are in war-torn countries or other dangerous areas.\n\n\n== Diplomatic Security ==\nThe Regional Security Office is staffed by Special Agents of the Diplomatic Security Service (DSS), and is responsible for all security, protection, and law enforcement operations in the embassy or consulate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kidney_dialysis">Kidney dialysis</a></td>
      <td>In medicine, dialysis (from Greek διάλυσις, dialysis, 'dissolution'; from διά, dia, 'through', and λύσις, lysis, 'loosening or splitting') is the process of removing excess water, solutes, and toxins from the blood in people whose kidneys can no longer perform these functions naturally. This is referred to as renal replacement therapy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reimbursement">Reimbursement</a></td>
      <td>Reimbursement is the act of compensating someone for an out-of-pocket expense by giving them an amount of money equal to what was spent.Companies, governments and nonprofit organizations may compensate their employees or officers for necessary and reasonable expenses; under US\nlaw, these expenses may be deducted from taxes by the organization and treated as untaxed income for the recipient provided that accountability conditions are met. UK law provides for deductions for travel and subsistence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ERISA_reimbursement">ERISA reimbursement</a></td>
      <td>In the United States, ERISA reimbursement refers to the efforts of an ERISA Plan administrator (an insurer) to obtain repayment from an insured person who had previously received payments for personal injury medical bills.When an insurer pays a injury claim to someone, the insurer can seize cash settlements from whoever caused the injury. This “right of reimbursement” is essentially a subrogation claim.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fee_Reimbursement_Scheme_(Andhra_Pradesh)">Fee Reimbursement Scheme (Andhra Pradesh)</a></td>
      <td>The Fee Reimbursement Scheme (also known as the Post-matric Scholarship Scheme) is a student education sponsorship programme of the Government of Andhra Pradesh. It supports students from lower economic strata in the state.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/End_Stage_Renal_Disease_Program">End Stage Renal Disease Program</a></td>
      <td>In 1972 the United States Congress passed legislation authorizing the End Stage Renal Disease Program (ESRD) under Medicare. Section 299I of Public Law 92-603, passed on October 30, 1972, extended Medicare coverage to Americans if they had stage five chronic kidney disease (CKD) and were otherwise qualified under Medicare's work history requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profit_(economics)">Profit (economics)</a></td>
      <td>An economic profit is the difference between the revenue a  commercial entity has received from its outputs and the opportunity costs of its inputs. It equals to total revenue minus total cost, including both explicit and implicit costs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_analysis">Profitability analysis</a></td>
      <td>In cost accounting, profitability analysis is an analysis of the profitability of an organisation's output. Output of an organisation can be grouped into products, customers, locations, channels and/or transactions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_index">Profitability index</a></td>
      <td>Profitability index (PI), also known as profit investment ratio (PIR) and value investment ratio (VIR), is the ratio of payoff to investment of a proposed project. It is a useful tool for ranking projects because it allows you to quantify the amount of value created per unit of investment.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_Profitability_Analysis">Customer Profitability Analysis</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Small_Is_Profitable">Small Is Profitable</a></td>
      <td>Small Is Profitable: The Hidden Economic Benefits of Making Electrical Resources the Right Size is a 2002 book by energy analyst Amory Lovins and others.  The book describes 207 ways in which the size of "electrical resources"—devices that make, save, or store electricity—affects their economic value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitable_growth">Profitable growth</a></td>
      <td>Profitable Growth is the combination of profitability and growth, more precisely the combination of Economic Profitability and Growth of Free cash flows. Profitable growth is aimed at seducing the financial community; it emerged in the early 80s when shareholder value creation became firms’ main objective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_profitability">Customer profitability</a></td>
      <td>Customer profitability (CP) is the profit the firm makes from serving a customer or customer group over a specified period of time, specifically the difference between the revenues earned from and the costs associated with the customer relationship in a specified period. According to Philip Kotler,"a profitable customer is a person, household or a company that overtime, yields a revenue stream that exceeds by an acceptable amount the company's cost stream of attracting, selling and servicing the customer."\nCalculating customer profit is an important step in understanding which customer relationships are better than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/SAP_ERP">SAP ERP</a></td>
      <td>SAP ERP is an enterprise resource planning software developed by the German company SAP SE. SAP ERP incorporates the key business functions of an organization. The latest version of SAP ERP (V.6.0) was made available in 2006.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porter's_five_forces_analysis">Porter's five forces analysis</a></td>
      <td>Porter's Five Forces Framework is a method of analysing the operating environment of a competition of a business. It draws from industrial organization (IO) economics to derive five forces that determine the competitive intensity and, therefore, the attractiveness (or lack thereof) of an industry in terms of its profitability.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>DIALYSIS CORP OF AMERICA      Item 1A Risk Factors       We  have listed below certain of the <font color="blue">risk factors</font> relating to <font color="blue">Dialysis </font>    Corporation of America and our securities</td>
    </tr>
    <tr>
      <td>There may be other risks and     <font color="blue">uncertainties</font> that we may face and of which we are <font color="blue">currently unaware which</font>     could  also  <font color="blue">adversely</font>  affect  our business, <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>If any of such risks or <font color="blue">uncertainties</font> arise, or the <font color="blue">risks listed</font>     below occur, our <font color="blue">operations</font>, earnings and <font color="blue"><font color="blue">financial condition</font> could</font> be     materially harmed, which, in turn, would most likely <font color="blue">adversely</font> affect the     <font color="blue">trading price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">such event could negatively impact</font> a     shareholder’s <font color="blue">investment</font> in the company</td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________       Until fiscal 2001, we had experienced <font color="blue">operational losses</font>       Since  1989,  when  we  sold four of our <font color="blue">five <font color="blue"><font color="blue">dialysis center</font>s</font></font>, we had     experienced <font color="blue">operational losses</font></td>
    </tr>
    <tr>
      <td>Not until fiscal 2001 did we <font color="blue">reflect net</font>     income</td>
    </tr>
    <tr>
      <td>We initiated an <font color="blue">expansion program</font> in 1995, opening two new dialysis     centers that year, and to date operate and/or manage 29 centers in the     states of Georgia, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and     South  Carolina,  and we have five centers in <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Some of our     dialysis  centers  have  generated  losses since their <font color="blue">commencement</font> of     <font color="blue">operations</font> and, although typical to newly established <font color="blue">facilities</font>, some     continue to generate losses after 12 months of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>This is due to     <font color="blue">operational costs</font> and time needed to <font color="blue">reach maturity</font> of <font color="blue">dialysis <font color="blue">treatments</font></font></td>
    </tr>
    <tr>
      <td>See Item 7, “Management’s Discussion and Analysis of Financial Condition and     <font color="blue">Results of Operations</font></td>
    </tr>
    <tr>
      <td>”       <font color="blue">Dialysis </font><font color="blue">operations</font> are subject to extensive <font color="blue"><font color="blue">government</font> regulation</font>       Our  dialysis  <font color="blue">operations</font>  are  subject to extensive federal and state     <font color="blue"><font color="blue">government</font> regulation</font>s, which include:       ·     <font color="blue">licensing <font color="blue">requirements</font></font> for <font color="blue">each <font color="blue">dialysis center</font></font>       ·     <font color="blue">government</font> healthcare program participation <font color="blue">requirements</font>       ·     <font color="blue">reimbursement</font> for <font color="blue">patient services</font>       ·     patient referral <font color="blue">prohibitions</font>; broad federal and state anti-kickback     <font color="blue">regulations</font>       ·     false claims <font color="blue">prohibitions</font> for health care <font color="blue">reimbursement</font> and other fraud and     abuse <font color="blue">regulations</font>       ·     record keeping <font color="blue">requirements</font>       ·     health, safety and <font color="blue"><font color="blue">environment</font>al compliance</font>       ·     <font color="blue">expanded protection</font> of the privacy and security of <font color="blue">personal medical data</font>       ·     standards for the exchange of <font color="blue">electronic</font> health information; <font color="blue">electronic</font>     <font color="blue">transactions</font> and code sets; unique identifiers for providers       ·     medical waste disposal <font color="blue">regulations</font>       Many of these laws and <font color="blue">regulations</font> are complex and open to further judicial     and <font color="blue">legislative</font> <font color="blue"><font color="blue">interpretation</font>s</font></td>
    </tr>
    <tr>
      <td>If we are forced to change our method of     <font color="blue">operations</font> because of these <font color="blue">regulations</font>, our earnings, <font color="blue">financial condition</font>     and business could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>The imposition of <font color="blue">additional</font>     licensing  and  other <font color="blue">regulatory</font> <font color="blue">requirements</font> may, among other things,     increase our cost of doing business</td>
    </tr>
    <tr>
      <td>In addition, any violation of these     <font color="blue"><font color="blue">government</font>al</font>  <font color="blue">regulations</font> could involve substantial civil and criminal     penalties and fines, revocation of our licenses, closure of one or more of     our centers, and our <font color="blue">exclusion from participating</font> in <font color="blue"><font color="blue">Medicare and Medicaid </font>    </font>programs</td>
    </tr>
    <tr>
      <td>Any loss of federal or state <font color="blue">certifications</font> or <font color="blue">licenses would</font>     materially <font color="blue">adversely</font> impact our business</td>
    </tr>
    <tr>
      <td>In February, 2005, CMS published a <font color="blue">proposed rule</font> that <font color="blue">would revise</font> the     <font color="blue">conditions</font> for coverage for dialysis <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>The revised <font color="blue">conditions</font>     <font color="blue">would establish performance expectations</font> and <font color="blue">promote continuous quality</font>     <font color="blue">improvement</font></td>
    </tr>
    <tr>
      <td>These rules are subject to revision and would not become     <font color="blue"><font color="blue">effective</font> until issued</font> in final form</td>
    </tr>
    <tr>
      <td>Until the rules are finalized, it is     impossible  to  predict what impact any revisions to the <font color="blue">conditions</font> of     <font color="blue">coverage will</font> have on our business or our operating results</td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________       Our <font color="blue">arrangements with</font> our <font color="blue">physician <font color="blue">medical director</font>s</font> do not meet the safe     <font color="blue">harbor provisions</font> of federal and state laws, and may subject us to greater     <font color="blue"><font color="blue">government</font>al</font> scrutiny       Neither our <font color="blue">arrangements with</font> the <font color="blue">medical director</font>s of our <font color="blue">facilities</font>,     typically  retained <font color="blue">by us as independent contractors under</font> a fixed fee     medical  director  <font color="blue">agreement</font>,  nor the <font color="blue">minority <font color="blue">ownership interests</font></font> of     physicians  in  certain  of  our  dialysis  <font color="blue">facilities</font> meet all of the     <font color="blue">requirements</font> of <font color="blue">safe harbors</font> to the Anti-Kickback Statute and similar state     laws</td>
    </tr>
    <tr>
      <td>These <font color="blue">laws impose civil</font> and <font color="blue">criminal sanctions on persons</font> who receive     or make payments for referring a patient for treatment that is paid for in     whole  or  in  part  by  Medicare, Medicaid or similar state programs</td>
    </tr>
    <tr>
      <td><font color="blue">Transactions </font>that do not <font color="blue">fall within</font> a <font color="blue">safe harbor may</font> be subject to greater     <font color="blue">scrutiny by enforcement agencies</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> are subject to <font color="blue">Medicare and Medicaid </font><font color="blue">audits with concurrent</font>     <font color="blue">potential civil</font> and <font color="blue">criminal penalties</font> for failure to comply       We are subject to <font color="blue">periodic audits by</font> the <font color="blue">Medicare and Medicaid </font>programs,     which  have  various  rights  and remedies if they assert that we have     overcharged the programs or failed to comply with program <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Rights and remedies available under these programs include repayment of any     amounts alleged to be <font color="blue">overpayments</font> or in violation of program <font color="blue">requirements</font>,     or making <font color="blue">deductions from future amounts due</font> to us</td>
    </tr>
    <tr>
      <td>These <font color="blue">programs may also</font>     impose fines, <font color="blue">criminal penalties</font> or <font color="blue">program exclusions</font></td>
    </tr>
    <tr>
      <td>In the ordinary course of our business, we receive notices of <font color="blue">deficiencies</font>     for failure to comply with various <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">review such</font>     notices and take <font color="blue">appropriate corrective action</font></td>
    </tr>
    <tr>
      <td>In most cases, we and the     <font color="blue">reviewing agency will agree upon</font> the measures that will bring the center or     <font color="blue">services into compliance</font></td>
    </tr>
    <tr>
      <td>In some cases or upon repeat violations, none of     which we have experienced, the <font color="blue">reviewing agency may</font> take <font color="blue">various adverse</font>     <font color="blue">actions against</font> a provider, including but not limited to:       ·     the imposition of fines;       ·     suspension of payments for <font color="blue">new admissions</font> to the center; and       ·     in extreme circumstances, decertification from participation in the <font color="blue">Medicare     </font>or Medicaid programs and revocation of a center’s license</td>
    </tr>
    <tr>
      <td>Any such <font color="blue">regulatory</font> <font color="blue">actions could</font> <font color="blue">adversely</font> affect a center’s ability to     continue to operate, to provide certain services, and/or its <font color="blue">eligibility</font> to     <font color="blue">participate</font> in <font color="blue">Medicare or Medicaid </font>programs or to receive <font color="blue">payments from</font>     other payors</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">regulatory</font> <font color="blue">actions against</font> one center may subject     our  other  centers,  which  may be deemed under our <font color="blue">common control</font> or     ownership, to similar <font color="blue">adverse remedies</font></td>
    </tr>
    <tr>
      <td>There has been increased <font color="blue"><font color="blue">government</font>al</font> focus and <font color="blue">enforcement with respect</font> to     anti-fraud <font color="blue">initiatives</font> as they relate to healthcare providers       State and federal <font color="blue"><font color="blue">government</font>s</font> are devoting increased attention and resources     to anti-fraud <font color="blue">initiatives</font> against healthcare providers</td>
    </tr>
    <tr>
      <td><font color="blue">Legislation </font>has     expanded the penalties for <font color="blue">healthcare fraud</font>, including <font color="blue">broader powers</font> to     exclude  providers  from  the  <font color="blue">Medicare and Medicaid </font>programs</td>
    </tr>
    <tr>
      <td>We have     <font color="blue">established policies</font> and procedures that we believe are sufficient to ensure     that  our <font color="blue">facilities</font> will operate in substantial <font color="blue">compliance with</font> these     anti-fraud <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>While we believe that our business practices are     <font color="blue">consistent with</font> <font color="blue">Medicare and Medicaid </font>criteria, those criteria are often     vague and subject to change and <font color="blue">interpretation</font></td>
    </tr>
    <tr>
      <td>Anti-fraud <font color="blue">actions could</font>     have an adverse effect on our <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________       Our revenues and <font color="blue">financial stability</font> are <font color="blue">dependent on</font> fixed <font color="blue">reimbursement</font>     <font color="blue">rates under</font> <font color="blue"><font color="blue">Medicare and Medicaid </font>    </font>  During 2003, 2004 and 2005, <font color="blue">approximately</font> 54prca , 48prca and 51prca, respectively of     our <font color="blue">patient revenues</font> was <font color="blue">derived from</font> Medicare <font color="blue">reimbursement</font>, and 8prca of our     patient  revenues in each of these years was <font color="blue">derived from</font> Medicaid and     equivalent programs</td>
    </tr>
    <tr>
      <td><font color="blue">Decreases </font>in <font color="blue">Medicare and Medicaid </font>and equivalent rates     and programs for our <font color="blue">dialysis <font color="blue">treatments</font></font> would <font color="blue">adversely</font> affect our revenues     and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Federal and state <font color="blue"><font color="blue">government</font>s</font> seek to maintain, if not reduce, costs, and     any such actions in the <font color="blue">healthcare industry</font> could <font color="blue">adversely</font> affect our     revenues and earnings, including the following:       ·     <font color="blue">reductions</font> in payments to us or <font color="blue"><font color="blue">government</font> programs</font> in which we <font color="blue">participate</font>       ·     increases in labor and supply costs, which we do experience, without     comparable <font color="blue"><font color="blue">government</font>al</font> <font color="blue">reimbursement</font> rate increases       ·     inclusion in the <font color="blue">flat <font color="blue">composite rate</font></font> for <font color="blue">dialysis <font color="blue">treatments</font></font> those <font color="blue">ancillary</font>     <font color="blue">services which</font> we <font color="blue">currently bill separately</font>       In November, 2005, CMS released the <font color="blue">final physician fee schedule</font> for 2006</td>
    </tr>
    <tr>
      <td>A     number of <font color="blue">provisions contained</font> in the <font color="blue">fee schedule will affect dialysis</font>     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>First, CMS revised the <font color="blue">geographic designations</font> and wage index     <font color="blue">adjustment applied</font> to the <font color="blue">composite payment rate</font></td>
    </tr>
    <tr>
      <td>CMS <font color="blue">will eliminate</font> the     wage index cap, currently set at 1dtta3, and will reduce the <font color="blue">wage index floor</font>     for  2006  to  0dtta85 from 0dtta98</td>
    </tr>
    <tr>
      <td><font color="blue">Revisions </font>to the <font color="blue">geographic adjustments</font>     applicable to <font color="blue"><font color="blue">composite rate</font> payments will</font> be phased in over a four year     period</td>
    </tr>
    <tr>
      <td>For 2006, 75prca of the <font color="blue">wage adjusted <font color="blue">composite rate</font> will reflect</font> the     old <font color="blue">geographic adjustments</font> and 25prca will reflect the <font color="blue">revised adjustments</font></td>
    </tr>
    <tr>
      <td>CMS  also  revised  its  <font color="blue">drug payment methodology</font>, moving from average     <font color="blue"><font color="blue">acquisition</font> cost pricing</font> to average sales price plus 6prca</td>
    </tr>
    <tr>
      <td>While these rates     will result in <font color="blue">lower payments</font> for <font color="blue">pharmaceuticals</font>, the <font color="blue">composite rate</font> was     <font color="blue">concurrently increased with</font> a revision to the drug add-on adjustment from     1dtta087 to 1dtta147</td>
    </tr>
    <tr>
      <td>CMS is continuing the <font color="blue">case mix adjustments finalized</font> in 2005     whereby  providers  receive higher <font color="blue">composite rate</font> payments for certain     <font color="blue">patients based on age</font>, body mass index and body <font color="blue">surface area</font></td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>does not believe that in the aggregate these changes in <font color="blue">Medicare     </font><font color="blue">reimbursement</font>  have <font color="blue"><font color="blue">significantly</font> impacted</font> our <font color="blue">operations</font>, expenses or     earnings</td>
    </tr>
    <tr>
      <td>Future changes in the structure of, and payment <font color="blue">rates under</font>, the     Medicare <font color="blue">program could substantially reduce</font> our earnings</td>
    </tr>
    <tr>
      <td><font color="blue">Decreases </font>in <font color="blue">reimbursement</font> <font color="blue">payments from</font> third-party, non-<font color="blue">government</font> payors     could <font color="blue">adversely</font> affect our earnings       Any reduction in the rates paid by private insurers, hospitals and other     non-<font color="blue"><font color="blue">government</font>al</font>  third-party organizations would <font color="blue">adversely</font> affect our     business</td>
    </tr>
    <tr>
      <td>Alternatively, any change in patient coverage, such as <font color="blue">Medicare     </font><font color="blue">eligibility</font> as opposed to higher private <font color="blue">insurance coverage</font>, would result in     a reduction of revenue</td>
    </tr>
    <tr>
      <td>We estimate <font color="blue">approximately</font> 38prca, 44prca and 41prca of our     <font color="blue">patient revenues</font> for 2003, 2004 and 2005, respectively, was obtained from     sources  other  than  <font color="blue">Medicare or Medicaid </font>and equivalent programs</td>
    </tr>
    <tr>
      <td>We     generally charge non-<font color="blue"><font color="blue">government</font>al</font> organizations for <font color="blue">dialysis treatment rates</font>     which  exceed the fixed <font color="blue">Medicare and Medicaid </font>and equivalent rates</td>
    </tr>
    <tr>
      <td>If     <font color="blue">private payors reduce</font> their payments or we experience a shift in <font color="blue">revenue mix</font>     toward <font color="blue">Medicare or Medicaid </font><font color="blue">reimbursement</font>, then our revenue, <font color="blue">cash flow</font> and     earnings  would  decrease,  and  our  cash  flow  and <font color="blue">profits would</font> be     <font color="blue">disproportionately affected</font></td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________       Any decrease in the <font color="blue">availability</font> of or the <font color="blue">reimbursement</font> rate of EPO would     reduce our revenues and earnings       EPO, a bio-engineered drug used for treating anemia in <font color="blue">dialysis patients</font>, is     currently available from a single <font color="blue">manufacturer</font>, Amgen, Inc</td>
    </tr>
    <tr>
      <td>There currently     is <font color="blue">no alternative drug available</font> to us for the treatment of anemia of our     <font color="blue">dialysis patients</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">available supply</font> of EPO could be delayed or reduced,     <font color="blue">whether by</font> Amgen itself, through unforeseen circumstances, or as a result of     <font color="blue">excessive demand</font></td>
    </tr>
    <tr>
      <td>In addition, Amgen <font color="blue">could increase</font> the price of EPO This     would <font color="blue">adversely</font> impact our revenues and <font color="blue">profitability</font>, since <font color="blue">approximately</font>     28prca of our <font color="blue">medical revenues</font> in each of 2003, 2004 and 2005 were <font color="blue">based upon</font>     the <font color="blue">administration</font> of EPO to our <font color="blue">dialysis patients</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">government</font> or <font color="blue">private payors reduce</font> <font color="blue">reimbursement</font> for EPO, then our     revenues and <font color="blue">earnings will decline</font></td>
    </tr>
    <tr>
      <td>Most of our EPO <font color="blue">reimbursement</font> is from     <font color="blue">government</font>  programs</td>
    </tr>
    <tr>
      <td>For  2005,  <font color="blue">Medicare and Medicaid </font><font color="blue">reimbursement</font>     represented 72prca of the total revenue <font color="blue">derived from</font> EPO In 2005, CMS revised     its  rules  for <font color="blue">reimbursement</font> of <font color="blue">pharmaceuticals</font>, including EPO, which     resulted in a <font color="blue">net reduction</font> of average Medicare <font color="blue">payment rates</font></td>
    </tr>
    <tr>
      <td>In 2006,     <font color="blue">reimbursement</font> for EPO will be at the average sales price plus 6prca, <font color="blue">which will</font>     result in lower <font color="blue">reimbursement</font> for <font color="blue">pharmaceuticals</font>, but offset by the 1dtta6prca     <font color="blue">composite rate</font> increase</td>
    </tr>
    <tr>
      <td><font color="blue">Changes in Medicare </font><font color="blue">reimbursement</font> criteria may also impact EPO revenue</td>
    </tr>
    <tr>
      <td>In     2005, CMS adopted a <font color="blue">national monitoring policy</font> for EPO claims</td>
    </tr>
    <tr>
      <td>This policy,     <font color="blue">which will</font> be <font color="blue">effective</font> April, 2006, may have an <font color="blue">adverse impact on</font> our net     revenue and earnings</td>
    </tr>
    <tr>
      <td>Under the new policy, CMS <font color="blue">will initiate monitoring</font>     when <font color="blue">patient <font color="blue">hematocrit levels</font> reach</font> a threshold of 39dtta0</td>
    </tr>
    <tr>
      <td>CMS expects a 25prca     reduction in the dosage of EPO for patients whose <font color="blue">hemotocrit</font> exceeds this     threshold</td>
    </tr>
    <tr>
      <td>If  dosage  is not reduced, payment will be made as if the     reduction had occurred</td>
    </tr>
    <tr>
      <td>The <font color="blue">policy also limits</font> the quantity of EPO that can     be <font color="blue">administered</font> in a month, regardless of <font color="blue">hematocrit levels</font></td>
    </tr>
    <tr>
      <td>We have revised     our <font color="blue">protocols on anemia <font color="blue">management</font></font> to address this policy</td>
    </tr>
    <tr>
      <td>The <font color="blue">implementation</font> of the case-mix adjustment could <font color="blue">adversely</font> affect our     revenues, <font color="blue">profitability</font> and <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>In April, 2005, CMS adopted a case-mix adjustment for the ESRD composite     rate,  under  which the Medicare <font color="blue">composite rate</font> is <font color="blue">adjusted based on</font> a     patient’s  age,  body mass index and body <font color="blue">surface area</font></td>
    </tr>
    <tr>
      <td>This change is     intended to <font color="blue">link payment</font> more closely to acuity and its <font color="blue">impact on revenues</font>     will turn on our <font color="blue">patient acuity mix</font></td>
    </tr>
    <tr>
      <td>For 2005, case-mix adjustment has not     <font color="blue">adversely</font> affected revenues or <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>New  Amgen  drug  could  affect  use  of  EPO, <font color="blue">adversely</font> impacting our     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Amgen is the sole <font color="blue">manufacturer</font> of EPO, which is <font color="blue">administered</font> in <font color="blue">conjunction</font>     with <font color="blue">dialysis <font color="blue">treatments</font></font> to address a patient’s anemia</td>
    </tr>
    <tr>
      <td>Amgen has developed     and obtained FDA approval for its new drug Aranesp®, used to <font color="blue">treat anemia</font>,     and which is indicated to be <font color="blue">effective</font> for a <font color="blue">longer period than</font> EPO Based     on its longer lasting capabilities, potential profit margins on Aranesp®     could be <font color="blue"><font color="blue">significantly</font> lower than on</font> EPO, and <font color="blue">furthermore</font>, Aranesp® could be     <font color="blue">administered</font>  by  a  dialysis patient’s physician, further eliminating     <font color="blue">potential revenues from</font> the treatment of anemia in our <font color="blue">dialysis patients</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">introduction</font> of Aranesp® as an <font color="blue">anemia treatment</font> for <font color="blue">dialysis patients</font>,     therefore, could <font color="blue">adversely</font> impact our revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________       Our ability to grow is subject to our resources and <font color="blue">available locations</font>       Other <font color="blue">than four center <font color="blue">acquisition</font>s over</font> the period 2002 through 2004 and     three  centers acquired in the <font color="blue">first quarter</font> of 2006, expansion of our     <font color="blue">operations</font> has <font color="blue">been through construction</font> of <font color="blue"><font color="blue">dialysis center</font>s</font></td>
    </tr>
    <tr>
      <td>We developed     two <font color="blue"><font color="blue">dialysis center</font>s</font> and acquired <font color="blue">one <font color="blue">facility</font></font> in 2003, opened five new     centers and acquired a company with two dialysis <font color="blue">facilities</font> in 2004, opened     <font color="blue">three <font color="blue">new centers</font></font> in 2005, have four centers under <font color="blue">development</font>, and have     acquired <font color="blue">three centers</font> in early 2006</td>
    </tr>
    <tr>
      <td>We <font color="blue">seek areas with qualified</font> and     cost-<font color="blue">effective</font> nursing and <font color="blue">technical personnel</font> and a <font color="blue">sufficient population</font>     to sustain a <font color="blue">dialysis center</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">opportunities</font> are limited and we compete     with much <font color="blue">larger dialysis companies</font> for <font color="blue"><font color="blue">appropriate location</font>s</font></td>
    </tr>
    <tr>
      <td>The time     <font color="blue">period from</font> the beginning of construction through <font color="blue">commencement</font> of <font color="blue">operations</font>     of  a <font color="blue">dialysis center</font> generally takes four to six months and sometimes     longer</td>
    </tr>
    <tr>
      <td>Once the center is operable, it generates revenues, but usually does     not operate at full <font color="blue">capacity</font>, and may incur losses for <font color="blue">approximately</font> 12     months or longer</td>
    </tr>
    <tr>
      <td>Our <font color="blue">growth strategy based on construction also involves</font>     the  risks  of  our  ability to identify <font color="blue">suitable locations</font> to develop     <font color="blue">additional</font> centers</td>
    </tr>
    <tr>
      <td>Those we do develop may never achieve <font color="blue">profitability</font>, and     <font color="blue">additional</font> financing may not be available to finance future <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to acquire or develop <font color="blue"><font color="blue">dialysis center</font>s</font> in a cost-<font color="blue">effective</font>     manner would <font color="blue">adversely</font> affect our ability to expand our business and as a     result, our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Growth <font color="blue">places significant demands on</font> our financial and <font color="blue"><font color="blue">management</font> skills</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inability </font>on our behalf to meet the <font color="blue">challenges</font> of expansion and to manage     any <font color="blue">such growth would</font> have an adverse effect on our results of <font color="blue">operations</font>     and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our attempt to expand through <font color="blue">development</font> or <font color="blue">acquisition</font> of <font color="blue"><font color="blue">dialysis center</font>s</font>     which are not currently identified <font color="blue">entails risks which <font color="blue">shareholders</font></font> and     <font color="blue">investors will</font> not have a basis to evaluate       We <font color="blue">expand generally by seeking</font> an <font color="blue">appropriate location</font> for <font color="blue">development</font> of a     <font color="blue">dialysis center</font> and by taking <font color="blue">into consideration</font> the <font color="blue">potential geographic</font>     <font color="blue">patient base</font>, and the <font color="blue">availability</font> of a <font color="blue">physician nephrologist</font> to be our     <font color="blue">medical director</font> and a skilled work force</td>
    </tr>
    <tr>
      <td>Construction, equipment and     initial working <font color="blue">capital costs</font> for a new <font color="blue">dialysis center</font> with 15 stations,     typically  the size of our dialysis <font color="blue">facilities</font>, range from dlra750cmam000 to     dlra1cmam000cmam000</td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that we will be successful in developing or acquiring     dialysis <font color="blue">facilities</font>, or <font color="blue">otherwise successfully expanding</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We     are <font color="blue">negotiating with nephrologists</font> and others to <font color="blue">establish new dialysis</font>     centers, but we <font color="blue">cannot assure</font> you that these <font color="blue">negotiations will</font> result in the     <font color="blue">development</font> of <font color="blue">new centers</font></td>
    </tr>
    <tr>
      <td>Furthermore, there is no basis for <font color="blue">shareholders</font>     and investors to evaluate the <font color="blue">specific merits</font> or risks of any potential     <font color="blue">development</font> or <font color="blue">acquisition</font> of dialysis <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________       We <font color="blue">depend on physician referrals</font>, and the <font color="blue">limitation</font> or cessation of such     referrals would <font color="blue">adversely</font> impact our revenues and earnings       Most dialysis <font color="blue">facilities</font>, including ours, are <font color="blue"><font color="blue">dependent upon</font> referrals</font> of     ESRD  patients for treatment by physicians, primarily those physicians     <font color="blue">specializing</font>  in  <font color="blue">nephrology</font></td>
    </tr>
    <tr>
      <td>We retain by written <font color="blue">agreement</font> qualified     physicians or groups of <font color="blue">qualified physicians</font> to serve as <font color="blue">medical director</font>s     for each of our <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">medical director</font>s are typically a source of     <font color="blue">patients treated at</font> the <font color="blue">particular <font color="blue">facility</font> served</font></td>
    </tr>
    <tr>
      <td>There is <font color="blue">no requirement</font>     for these physicians to refer their patients to us, and they are free to     <font color="blue">refer patients</font> to any other <font color="blue">dialysis <font color="blue">facility</font></font></td>
    </tr>
    <tr>
      <td>The loss of the <font color="blue">patient base</font>     of the <font color="blue">medical director</font> or other physicians in the area of our <font color="blue">facilities</font>     could result in a decline in our <font color="blue">operations</font>, revenues and earnings</td>
    </tr>
    <tr>
      <td>We may     not be able to renew or <font color="blue">otherwise negotiate compensation under</font> the medical     director  <font color="blue">agreement</font>s  with our <font color="blue">medical director</font> physicians which could     terminate  the  <font color="blue">relationship</font>,  and without a suitable <font color="blue">medical director</font>     <font color="blue">replacement could</font> result in closure of the <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Accordingly, the loss     of these key physicians at a particular <font color="blue">facility</font> could have a material     adverse effect on the <font color="blue">operations</font> of the <font color="blue">facility</font> and could <font color="blue">adversely</font> affect     our revenues and earnings</td>
    </tr>
    <tr>
      <td>Most of our <font color="blue">medical director</font> <font color="blue">agreement</font>s range in     terms of from five to ten years with renewals</td>
    </tr>
    <tr>
      <td>We have had <font color="blue">no <font color="blue">difficult</font>y</font> in     renewing  <font color="blue">agreement</font>s  as  they  have expired</td>
    </tr>
    <tr>
      <td>All the <font color="blue">medical director</font>     <font color="blue">agreement</font>s provide for <font color="blue">non<font color="blue">competition</font></font> <font color="blue">restrictions</font></td>
    </tr>
    <tr>
      <td>We have never had to     attempt to enforce such <font color="blue">restrictions</font>, but there is no assurance that a     <font color="blue">particular jurisdiction</font> in which the <font color="blue">agreement</font> is <font color="blue">applicable would uphold</font>     such  <font color="blue">non<font color="blue">competition</font></font> <font color="blue">agreement</font>, which would increase the potential for     <font color="blue">competition</font> with affiliated <font color="blue"><font color="blue">dialysis center</font>s</font> and could <font color="blue">adversely</font> impact our     revenues and earnings</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">medical director</font>s or the <font color="blue">medical groups with whom</font> they are     associated own <font color="blue">minority interests</font> in certain of our <font color="blue">subsidiaries which</font>     operate  dialysis  centers</td>
    </tr>
    <tr>
      <td>If  these interests are deemed to violate     <font color="blue">applicable federal</font> or state law, these <font color="blue">physicians may</font> be forced to dispose     of their <font color="blue">ownership interests</font></td>
    </tr>
    <tr>
      <td><font color="blue">Industry </font>changes could <font color="blue">adversely</font> affect our business       <font color="blue">Healthcare </font>organizations, public and private, continue to change the manner     in which they operate and pay for services</td>
    </tr>
    <tr>
      <td>Our business is designed to     <font color="blue">function within</font> the <font color="blue">current healthcare financing</font> and <font color="blue">reimbursement</font> system</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, the <font color="blue">healthcare industry</font> has been subject to increasing     levels  of  <font color="blue">government</font>  regulation  of <font color="blue">reimbursement</font> rates and capital     expenditures, among other things</td>
    </tr>
    <tr>
      <td>In addition, proposals to reform the     <font color="blue">healthcare system</font> have been considered by Congress, and still remain a     priority issue</td>
    </tr>
    <tr>
      <td>Any new <font color="blue">legislative</font> <font color="blue">initiatives</font>, if enacted, may (i) further     increase <font color="blue"><font color="blue">government</font> regulation</font> of or other <font color="blue">involvement</font> in healthcare, (ii)     lower  <font color="blue">reimbursement</font>  rates,  and (iii) otherwise change the operating     <font color="blue">environment</font> for <font color="blue">healthcare companies</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the likelihood of     those  events  or what impact they may have on our earnings, financial     condition or business</td>
    </tr>
    <tr>
      <td>Our business is subject to substantial <font color="blue">competition</font>, and we <font color="blue">must compete</font>     <font color="blue">effective</font>ly, otherwise our <font color="blue">growth could slow</font>       We are operating in a highly competitive <font color="blue">environment</font> in terms of operation,     <font color="blue">development</font> and <font color="blue">acquisition</font> of existing <font color="blue"><font color="blue">dialysis center</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competition</font>     <font color="blue">comes from</font> other <font color="blue"><font color="blue">dialysis center</font>s</font>, many of which are owned by much larger     companies,  and  from  hospitals</td>
    </tr>
    <tr>
      <td>The  dialysis  industry  is rapidly     <font color="blue">consolidating</font>, resulting in several very large <font color="blue">dialysis companies competing</font>     for the <font color="blue">acquisition</font> of existing <font color="blue"><font color="blue">dialysis center</font>s</font> and the <font color="blue">development</font> of     <font color="blue">relationship</font>s  <font color="blue">with referring physicians</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have     <font color="blue">significantly</font> greater financial resources, more dialysis <font color="blue">facilities</font> and a     <font color="blue">significantly</font> larger <font color="blue">patient base</font></td>
    </tr>
    <tr>
      <td>In addition, technological advances by     our <font color="blue">competitors</font> may provide more <font color="blue">effective</font> <font color="blue">dialysis <font color="blue">treatments</font></font> than the     <font color="blue">services provided by</font> our centers</td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________       We <font color="blue">also compete with physicians</font> who open their own dialysis <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for existing centers has increased the costs of acquiring such     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>is <font color="blue">also intense</font> for <font color="blue">qualified nursing</font> and technical     <font color="blue">staff as well as</font> for <font color="blue">nephrologists with</font> an adequate <font color="blue">patient base</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>we have <font color="blue">exhibited growth over</font> the <font color="blue">last several years</font>, we can <font color="blue">provide no</font>     assurance that we will be able to compete <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>Our failure to do so     <font color="blue">could impair</font> our <font color="blue">continued growth</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We could be subject to <font color="blue"><font color="blue">professional</font> <font color="blue">liability</font></font> claims that may <font color="blue">adversely</font>     <font color="blue">affect us</font>       <font color="blue">Operation </font>of <font color="blue"><font color="blue">dialysis center</font>s</font> and, in particular, the provision of dialysis     <font color="blue">treatments</font> to ESRD patients, as is the <font color="blue">case with most healthcare treatment</font>     services, entails significant risks of <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Accordingly, we could be     subject to <font color="blue">various actions</font> and claims of <font color="blue"><font color="blue">professional</font> <font color="blue">liability</font></font> alleging     negligence in the performance of our treatment and related services, as well     as for the acts or omissions of our employees</td>
    </tr>
    <tr>
      <td>As we grow and the number of     our <font color="blue">patients increases</font>, so too does our <font color="blue">exposure increase</font> to potential     malpractice, <font color="blue">professional</font> negligence, and other related <font color="blue">legal theories</font> and     causes of action</td>
    </tr>
    <tr>
      <td>These potential claims could seek substantial damages,     possibly  beyond  our  <font color="blue">insurance coverage</font>, and could subject us to the     incurrence of <font color="blue">significant fees</font> and costs related to <font color="blue">defending such potential</font>     claims</td>
    </tr>
    <tr>
      <td>Such  <font color="blue">potential future</font> claims for malpractice or <font color="blue">professional</font>     <font color="blue">liability</font>, including any judgments, settlements or <font color="blue">costs associated with</font>     such claims and actions, could have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>Our insurance costs and <font color="blue">deductibles</font> have been substantially <font color="blue">increasing over</font>     the <font color="blue">last several years</font>, and may not be sufficient to cover claims and losses       We maintain a program of <font color="blue">insurance coverage</font> against a <font color="blue">broad range</font> of risks     in  our  business,  including, and of primary importance, <font color="blue">professional</font>     <font color="blue">liability</font>  insurance, subject to certain <font color="blue">deductibles</font></td>
    </tr>
    <tr>
      <td>The premiums and     <font color="blue">deductibles</font> under our <font color="blue">insurance program</font> have <font color="blue">been steadily</font> and <font color="blue">significantly</font>     <font color="blue">increasing over</font> the <font color="blue">last several years</font> as a result of general business rate     <font color="blue">increases coupled with</font> our <font color="blue">continued growth</font> and <font color="blue">development</font> of dialysis     centers</td>
    </tr>
    <tr>
      <td>We  are  unable to <font color="blue">predict <font color="blue">further increases</font></font> in premiums and     <font color="blue">deductibles</font>, but based on experience we anticipate <font color="blue">further increases</font> in this     area, which would <font color="blue">adversely</font> impact earnings</td>
    </tr>
    <tr>
      <td>The <font color="blue">liability</font> exposure of     <font color="blue">operations</font> in the <font color="blue">healthcare services industry</font> has increased, resulting not     only  in increased premiums, but in limited <font color="blue">liability</font> on behalf of the     <font color="blue">insurance carriers</font></td>
    </tr>
    <tr>
      <td>Our ability to obtain the <font color="blue">necessary</font> and sufficient     <font color="blue">insurance coverage</font> for our <font color="blue">operations</font> upon expiration of our insurance     <font color="blue">policies may</font> be limited, and <font color="blue">sufficient <font color="blue">insurance may</font></font> not be <font color="blue">available on</font>     favorable terms, if at all</td>
    </tr>
    <tr>
      <td>Such <font color="blue">insurance may</font> not be sufficient to cover     any judgments, settlements or costs relating to <font color="blue">potential future</font> claims,     <font color="blue">complaints</font> or law suits</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to obtain <font color="blue">sufficient insurance</font> for     our <font color="blue">operations</font>, or if we obtain <font color="blue">insurance which</font> is limited, any future     significant judgments, settlements and costs relating to <font color="blue">future potential</font>     actions, suits or claims, could have an adverse effect on our company</td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________       The  loss  of  <font color="blue">certain executive personnel without</font> retaining qualified     <font color="blue">replacements</font>  could <font color="blue">adversely</font> affect our business <font color="blue">operations</font>, and as a     result, our revenues and <font color="blue">earnings could decline</font>       We are <font color="blue">dependent upon</font> the services of Thomas K Langbein, Chairman of the     Board, and Stephen W Everett, our President, Chief Executive Officer and a     director</td>
    </tr>
    <tr>
      <td>Langbein has <font color="blue"><font color="blue">been involved</font> with us since</font> we organized in 1976</td>
    </tr>
    <tr>
      <td>Everett joined our company in November, 1998 as Vice President, became     Executive <font color="blue">Vice <font color="blue">President </font></font>in June, 1999, <font color="blue">President </font>on March 1, 2000, and     Chief Executive Officer in May, 2003</td>
    </tr>
    <tr>
      <td>Everett has <font color="blue">been involved</font> in the     <font color="blue">healthcare industry</font> for 26 years</td>
    </tr>
    <tr>
      <td>Everett had an <font color="blue">employment</font> <font color="blue">agreement</font>     <font color="blue">with us through</font> <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>A new five-year <font color="blue">employment</font> <font color="blue">agreement</font> was     <font color="blue">entered into with</font> Mr</td>
    </tr>
    <tr>
      <td>Everett <font color="blue">effective</font> as of January 3, 2006</td>
    </tr>
    <tr>
      <td>Among other     things, the <font color="blue">employment</font> <font color="blue">agreement</font> contains a non-<font color="blue">competition</font> provision during     the term of the <font color="blue">agreement</font> and for one year after <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>It would be     very <font color="blue">difficult</font> to replace the services of these individuals, whose services,     both  <font color="blue">individually</font>  and  combined, if lost, would <font color="blue">adversely</font> affect our     <font color="blue">operations</font> and earnings, and <font color="blue">most likely as</font> a result, the <font color="blue">trading price</font> of     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>There is no key-man life insurance covering any of our     officers</td>
    </tr>
    <tr>
      <td>Shares eligible for future sale by restricted <font color="blue">shareholders</font> may <font color="blue">adversely</font>     affect our stock price       Our officers and <font color="blue">directors</font> own 2cmam340cmam675 shares of our <font color="blue">common stock</font> and     <font color="blue">vested options exercisable into</font> an <font color="blue">additional</font> 36cmam250 shares of <font color="blue">common stock</font>,     for  an  aggregate  of  2cmam376cmam925  shares or <font color="blue">approximately</font> 25prca of then     outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Most of the shares held by these officers and     <font color="blue">directors</font>, upon satisfying the <font color="blue">conditions</font> of Rule 144 under the Securities     Act, may be <font color="blue">sold without complying with</font> the <font color="blue">registration provisions</font> of the     <font color="blue">Securities Act</font></td>
    </tr>
    <tr>
      <td>Rule 144 <font color="blue">conditions</font> include:       ·     holding the shares for one year from <font color="blue">acquisition</font>;       ·     <font color="blue">volume limits</font> of <font color="blue">selling every three months</font> an amount of <font color="blue">shares which</font> does     not exceed the greater of 1prca of the outstanding <font color="blue">common stock</font>, or the average     <font color="blue">weekly volume</font> of <font color="blue">trading as</font> reported by Nasdaq during the <font color="blue">four calendar</font>     <font color="blue">weeks prior</font> to the sale;       ·     filing Form 144 with the SEC;       ·     the company continuing to timely file its reports under the Exchange Act;       Our publicly tradable <font color="blue">common stock</font>, known as the float, is <font color="blue">approximately</font>     7cmam165cmam000 shares</td>
    </tr>
    <tr>
      <td>Accordingly, the sale by     such officers and <font color="blue">directors</font> under Rule 144 may have an <font color="blue">adverse affect on</font> the     <font color="blue">market price</font> of our <font color="blue">common stock</font>, and may inhibit our ability to manage     <font color="blue">subsequent equity</font> or <font color="blue">debt financing</font></td>
    </tr>
    <tr>
      <td>Over  the last year, our stock price has exhibited <font color="blue">volatility</font>, and any     <font color="blue">investment</font> in our <font color="blue">common stock</font> may, therefore, decline for <font color="blue">reasons unrelated</font>     to our performance       Our <font color="blue">common stock</font> trades on the <font color="blue">Nasdaq SmallCap Market </font>under the symbol     “DCAI” The <font color="blue">market price</font> of our <font color="blue">common stock</font> has <font color="blue">exhibited significant</font>     <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td>Other than the <font color="blue">merger announcement on</font> March 15, 2005, and the continued     growth of the company, there was no information known to <font color="blue">management</font> that     would cause <font color="blue">significant <font color="blue">fluctuation</font></font> in the price of our <font color="blue">common stock</font>, or in     the <font color="blue">trading volume</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">renal care industry</font> has experienced continued and     <font color="blue">rapid <font color="blue">consolidation</font> as evidenced by</font> the <font color="blue">acquisition</font> by DaVita, Inc</td>
    </tr>
    <tr>
      <td>of     Gambro Healthcare, Inc</td>
    </tr>
    <tr>
      <td>in October 2005 and the prospective <font color="blue">acquisition</font> of     Renal Care Group, Inc</td>
    </tr>
    <tr>
      <td>by Fresenius Medical Care, AG This <font color="blue">consolidation</font>     among the <font color="blue">four larger dialysis service providers may</font> have <font color="blue">generated interest</font>     of the marketplace in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>29       _________________________________________________________________       Other factors that <font color="blue">could continue</font> to cause <font color="blue">fluctuation</font> in our <font color="blue">common stock</font>     include:       ·     changes in <font color="blue"><font color="blue">government</font> regulation</font>, whether <font color="blue">legislative</font>, enforcement or     <font color="blue">reimbursement</font> rates       ·     <font color="blue">third party</font> reports relating to the <font color="blue">dialysis industry</font> and our company     (unsolicited by <font color="blue">management</font>)       ·     <font color="blue">announcements by</font> <font color="blue">management</font> relating to the company’s performance or other     material events       ·     actions and <font color="blue">announcements by</font> our <font color="blue">competitors</font>       ·     the outlook for the <font color="blue">healthcare industry</font> generally       <font color="blue">Investors </font>should understand that in general, stock prices fluctuate for     <font color="blue">reasons unrelated</font> to operating results</td>
    </tr>
    <tr>
      <td>Any changes in the above discussed     factors, the <font color="blue">Medicare and Medicaid </font><font color="blue">reimbursement</font> rates in particular, or     general economic, political, global and market <font color="blue">conditions</font>, could result in a     decline in the <font color="blue">market price</font> and volume of trading in our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>